Combining immune checkpoint inhibitors with standard treatment regimens in advanced human epidermal growth factor receptor-2 positive gastric cancer patients  

作　　者：Sheng-Hu Zhang Wan Li Xi-Yan Chen Le-Le Nie 

机构地区：[1]Department of Oncology,Jingzhou Central Hospital,Jingzhou Hospital Affiliated to Yangtze university,Jingzhou 434020,Hubei Province,China [2]Department of Ultrasound Medicine,Jingzhou Central Hospital,Jingzhou Hospital Affiliated to Yangtze university,Jingzhou 434020,Hubei Province,China [3]Department of Medicine Imaging,The First People’s Hospital of Fuzhou City,Fuzhou 344000,Jiangxi Province,China [4]Department of General Surgery,The First People’s Hospital of Fuzhou City,Fuzhou 344000,Jiangxi Province,China

出　　处：《World Journal of Gastrointestinal Oncology》2025年第4期243-253,共11页世界胃肠肿瘤学杂志(英文)

基　　金：This study was approved by the ethics committee of the First People’s Hospital of Fuzhou City(No.FZ202103).

摘　　要：BACKGROUND Gastric cancer is one of the most common malignant tumors worldwide,with its incidence and mortality rates ranking among the highest in gastrointestinal cancers.The overexpression or gene amplification of human epidermal growth factor receptor 2(HER-2)occurs in approximately 15%-20%of gastric cancers and serves as a critical molecular target influencing prognosis and treatment out-comes.For patients with HER-2-positive gastric cancer,trastuzumab combined with platinum-based chemotherapy has been established as the standard first-line treatment.However,despite the demonstrated clinical benefits in prolonging survival,the overall efficacy remains limited.In recent years,with the successful application of immune checkpoint inhibitors(ICIs)in various malignant tumors,combining ICIs with existing standard treatment regimens has emerged as a promising approach to enhance the therapeutic efficacy of HER-2-positive gastric cancer.Nevertheless,the efficacy and prognostic factors of ICIs combined with trastuzumab and chemotherapy in HER-2-positive gastric cancer remain unclear.AIM To analyze the efficacy of ICIs combined with standard treatment regimens and the prognostic factors in patients with advanced HER-2-positive gastric cancer.METHODS Clinical data from 104 patients with advanced HER-2-positive gastric cancer who were treated at our hospital between March 2021 and May 2023 were retrospectively analyzed.Patients were divided into a control group(n=54,treated with trastuzumab combined with platinum-based chemotherapy as the standard regimen)and an observation group(n=50,treated with ICIs in addition to the standard regimen).The therapeutic efficacy,survival outcomes,and adverse reactions were compared between the two groups.Univariate and Cox multivariate analyses were performed to identify factors influencing patient prognosis.RESULTS With a median follow-up time of 14.6 months,there were no significant differences between the two groups in terms of objective response rate or disease control rate(P>0.05).

关 键 词：ADVANCED Human epidermal growth factor receptor 2-positive Gastric cancer Standard treatment regimen Immune checkpoint inhibitors Efficacy Safety Prognosis Influencing factors 

分 类 号：R73[医药卫生—肿瘤]